VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-a regulation. Murine embryonic stem (ES) cells in which the endogenous wildtype Vhl gene was replaced with the representative Type 2B VHL hotspot mutation R167Q (Vhl 2B/2B ) displayed preserved physiological regulation of both HIF factors with slightly greater normoxic dysregulation of HIF-2a. Differentiated Vhl 2B/2B -derived teratomas overexpressed joint HIF targets Vegf and EglN3 but not the HIF-1aspecific target Pfk1. Vhl 2B/2B teratomas additionally displayed a growth advantage over Vhl À/À -derived teratomas, suggestive of a tight connection between perturbations in the degree and ratio of HIF-1a and HIF-2a stabilization and cell growth. Vhl 2B/2B mice displayed midgestational embryonic lethality, whereas adult Vhl 2B/ þ mice exhibited susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at 12 months. Our experiments support a model in which the representative Type 2B R167Q mutant pVhl produces a unique profile of HIF dysregulation, thereby promoting tissue-specific effects on cell growth, development and tumor predisposition.
Introduction
Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited cancer susceptibility syndrome resulting from germline mutation of the VHL tumor suppressor gene that affects 1 in 36 000 live births in the US (Maher et al., 1991; Neumann and Wiestler, 1991) . Specific classes of VHL mutations predispose to different spectrums of morbidity-and mortality-causing clinical phenotypes of VHL disease: retinal and central nervous system hemangioblastoma, pheochromocytoma/paraganglioma and renal cell carcinoma with clear cell histology (ccRCC) Zbar et al., 1996) . Type 1 VHL mutations predispose to ccRCC and hemangioblastoma (Gallou et al., 2004) . Type 2 missense VHL mutations predispose to pheochromocytoma, either alone (Type 2C) or in combination with hemangioblastoma and a high (Type 2B) or low (Type 2A) risk of ccRCC (Clifford et al., 2001) . Finally, individuals with homozygosity for the germline R200W VHL mutation develop Chuvash polycythemia (CP), a rare benign congenital erythrocytosis with no associated cancer risk (Ang et al., 2002; Pastore et al., 2003) .
The VHL gene encodes a 30 kDa protein, pVHL (Latif et al., 1993; Iliopoulos et al., 1995) . Wild-type pVHL has been reported to have functions in diverse biological processes, including acting as the recognition domain for an E3 ubiquitin ligase complex (Iwai et al., 1999; Lisztwan et al., 1999) composed of elongins B and C (Duan et al., 1995; Kibel et al., 1995) , cullin-2 (Pause et al., 1997) , ROC1 (Rbx1) and an E2 conjugating enzyme (Iwai et al., 1999; Kamura et al., 2000) . pVHL E3 ligase activity targets hypoxia inducible factor (HIF)-a subunits (Iliopoulos et al., 1996; Maxwell et al., 1999; Cockman et al., 2000; Ohh et al., 2000) , a family of transcription factor subunits, including HIF-1a and HIF-2a.
Hypoxia inducible factor -1a and HIF-2a coordinate cellular and whole-organism responses to hypoxia and are controlled at the level of stability and activity by oxygen-dependent hydroxylation. In normoxic conditions, a family of prolyl hydroxylases (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001 Ivan et al., , 2002 mediates the hydroxylation of HIF-a prolyl residues (Pugh et al., 1997; Huang et al., 1998 Huang et al., , 2002 Jaakkola et al., 2001) , targeting HIF-a to pVHL for degradation (Hon et al., 2002; Min et al., 2002) . In hypoxic conditions, the prolyl hydroxylases are inactive (Jiang et al., 1997; Pugh et al., 1997; Epstein et al., 2001) , resulting in stabilized, transcriptionally active HIF-a. Stabilized HIF-a heterodimerizes with ARNT/ HIF-1b to activate the transcription of target genes Tian et al., 1997) . HIF-1a and HIF-2a target gene sets overlap in a highly context-dependent manner (Semenza, 2003) , but HIF-1a uniquely activates glycolytic enzymes (Hu et al., 2003) .
Several lines of evidence implicate the VHL/HIF axis in the initiation of renal tumorigenesis. First, biallelic inactivation of VHL and overexpression of HIF targets is observed in both VHL disease-associated renal lesions and also 70-90% of sporadic ccRCC tumors Kondo et al., 2002; Banks et al., 2006; Nickerson et al., 2008) . Second, the overexpression of HIF targets accounts for many histological and clinical features of ccRCC tumors, including their highly vascular natures and paraneoplastic erythrocytosis (Rathmell and Chen, 2008) . Third, Vhl loss in primary cells directly results in the upregulation of both HIF-1a and HIF-2a and recapitulates many features of RCC (Mack et al., 2003) . Finally, emerging evidence points to the degree of HIF dysregulation impacting renal tumorigenesis. In vitro studies of cDNA-expressed Type 2A and Type 2B mutant pVHL models revealed graded dysregulation of HIF-1a and HIF-2a (Cockman et al., 2000; Clifford et al., 2001) , correlating with the degree of risk for ccRCC (Type 1XType 2B>Type 2A; Knauth et al., 2006; Li et al., 2007) . Additionally, although Type 2B mutations are predicted to disrupt pVHL-elongin C interactions, preservation of HIF ubiquitylation activity has been observed, which would provide a permissive environment for HIF regulation (Hacker et al, 2008) . The profile of HIF dysregulation may also have ramifications for tumor predisposition, as selective HIF-2a stabilization has been observed in murine embryonic stem (ES) cells transgenic for a Type 2B mutant VHL gene (Rathmell et al., 2004) . These systems, in addition to showing mutation specificity, are sensitive to pVHL levels.
Existing mouse models of VHL disease use null (Gnarra et al., 1997) or conditional null (Haase et al., 2001; Ma et al., 2003) Vhl alleles, display homozygous embryonic lethality and show a high penetrance of hepatic angiomas, uncommon in the human disease. A Vhl gene replacement model of CP, however, was viable and conferred erythrocytosis in a milieu of very mild HIF-2a stabilization (Hickey et al., 2007) . To examine the activities of mutant pVHL relevant to human cancer, particularly with respect to missense mutation-specific effects on HIF regulation, we undertook a gene replacement approach to study Type 2B VHL disease in a mouse model. This model provides the first opportunity to examine the effect of VHL diseasecausing missense mutations in its premalignant context and under endogenous transcriptional, translational and post-translational regulation. Murine ES cells, homozygous for a representative mutant 2B Vhl allele, displayed mild HIF-2a stabilization but functionally preserved HIF-1a suppression. In vivo, although homozygosity for the mutant 2B Vhl allele conferred midgestational embryonic lethality, heterozygous Vhl 2B/ þ mice were viable and susceptible to carcinogen-promoted renal adenocarcinoma. Our genetic knock-in mouse model thus provides a species-congruent cellular system and in vivo model in which to further examine the contributions of Type 2B VHL missense mutation to VHL disease-associated cancers.
Results
Generation and characterization of Type 2B Vhl ES cell lines The Arginine 167-glutamine (R167Q) missense mutation is a hotspot in the human VHL gene with a tight genotype-phenotype correlation to Type 2B disease (Maher et al., 1991; Zbar et al., 1996) . Localized to the pVHL a helical domain (Figure 1a ), R167 is predicted to stabilize the a/b domain interface and interaction with elongin C (Ohh et al., 1999; Stebbins et al., 1999) . In the murine Vhl allele, this mutation corresponds to a guanine to alanine transition at position 518 (G518A).
To study the effect of 2B mutant pVhl on regulation of HIF-a and HIF targets, we targeted the endogenous murine Vhl locus with an R167Q mutant Vhl construct ( Figure 1b ) to generate Vhl 2B/ þ and Vhl 2B/2B ES cell lines. The targeting construct introduced a HindIII site, enabling the verification of recombination by Southern analysis (Figure 1c ), and the G518A mutation introduced a novel HpyIV restriction site for restrictionbased PCR genotyping ( Figure 1d ). Quantitative reverse transcriptase PCR (qRT-PCR) analysis in Vhl 2B/2B ES cells confirmed that 2B mutant Vhl was transcribed at wild-type levels (Figure 2a ). Vhl 2B/ þ cells expressed wildtype levels of pVhl, whereas Vhl 2B/2B cells expressed greatly reduced levels of the 2B mutant pVhl ( Figure 2b ). A similar reduction in detectable 2B mutant pVhl was also observed by immunoblot with an antibody raised against an alternate epitope suggesting that the reduced detection of 2B mutant pVhl was not because of epitope-masking alone. Rescue with MG-132 treatment was not observed, consistent with the reduced protein expression and incomplete MG-132 rescue observed in the CP Vhl gene replacement model (Hickey et al., 2007) .
Analysis of HIF and HIF target expression in Type 2B
Vhl ES cells The R167Q human pVHL mutation is predicted to destabilize the pVhl protein (Knauth et al., 2006) and to disrupt pVhl recruitment of elongin C , resulting in HIF factor dysregulation. ES cells in the presence or absence of the chemical hypoxia mimetic cobalt chloride (CoCl 2 ) were examined for HIF-1a ( Figure 2c ) and HIF-2a ( Figure 2d ) protein levels by immunoblot. Wild-type and Vhl 2B/ þ ES cells displayed low basal levels of HIF-1a and HIF-2a and responded to CoCl 2 exposure with induction of both factors. Vhl À/À ES cells displayed maximal stabilization of both HIF-1a and HIF-2a without further induction . In contrast, Vhl 2B/2B ES cells retained physiologic induction of both HIF-a factors with CoCl 2 . Although normoxic HIF-1a levels in Vhl 2B2/2B cells were similar to wild-type cells in independently derived clones (Figure 2c ), normoxic HIF-2a levels tended to be modestly elevated ( Figure 2d ). Qualitative comparisons were confirmed by densitometry analysis (Supplementary Figure 1) .
Hypoxia inducible factor -2a is transcriptionally inactive in ES cells (Hu et al., 2006) . To determine whether Vhl 2B/2B ES cells activate transcription of HIF target genes, we performed qRT-PCR for four known HIF target mRNAs (Figure 2e ): the joint HIF-1a and HIF-2a targets, such as vascular endothelial (VE) growth factor (Vegf), glucose transporter 1 (Glut1) and prolyl hydroxylase three (EglN3) and the HIF-1aspecific glycolytic enzyme phosphofructokinase (Pfk1). Vhl À/À ES cells displayed transcription of all four HIF target mRNAs relative to wild-type J1 cells (Po0.05): Vegf (4.26-fold), Glut1 (2.66-fold), EglN3 (11.80-fold) Figure 1 Type 2B Vhl mutation knock-in strategy and genotyping. (a) Human-Mouse pVHL protein alignment. The R167Q pVHL substitution representing human Type 2B VHL disease is embedded in a highly homologous region. (b) Type 2B mutant murine Vhl containing the G518A (R167Q) representative missense mutation (star) was prepared with site-directed mutagenesis and then cloned into the targeting vector as shown. Following electroporation of the targeting vector into J1 embryonic stem (ES) cells, neomycin and gancyclovir resistance was used to select clones with homologous recombination at the endogenous murine locus (Neo-in). Cre recombinase exposure in vitro or in vivo resulted in excision of the floxed Neo R cassette (Neo-out). (c) Southern blot genotyping distinguished between wild-type and targeted Vhl alleles based on the introduction of new HindIII restriction sites. HindIII-digested murine Vhl was detected with a probe recognizing the Vhl 3 0 untranslated region (UTR, bar). (d) Restriction PCR was used as an alternative genotyping strategy. Primers (arrows) flanking the targeted mutation generated a 300-bp PCR product. The novel restriction site introduced by the G518A mutation rendered the targeted Vhl-origin PCR product susceptible to HpyIV digestion.
and Pfk1 (2.32-fold). Two independently derived Vhl 2B/2B clones, in contrast, failed to significantly overtranscribe any of the four HIF targets, consistent with the observation that Vhl 2B/2B ES cells exhibit wild-type HIF-1a expression. Mirroring the qRT-PCR results, Vhl À/À ES cells secreted robust levels of Vegf protein (4.4-fold) compared with wild-type (Po0.01), whereas Vhl 2B/2B ES cells did not secrete measurable Vegf (Figure 2f ).
Type 2B Vhl promotes teratoma growth and vascularization
To observe the functional effects of Type 2B Vhl mutation, we differentiated our panel of ES cells in a teratoma assay. As expected from earlier studies (Rathmell et al., 2004) , Vhl À/À -derived teratomas displayed a growth disadvantage. In contrast, the presence of one or two Type 2B Vhl alleles conferred a persistent growth advantage, such that Vhl 2B/2B -derived teratomas grew faster than Vhl 2B/ þ -derived teratomas, which in turn grew faster than wild-type teratomas (Figure 3a ).
At harvest, J1, Vhl À/À and Vhl 2B/ þ teratomas were well encapsulated, whereas Vhl 2B/2B teratomas adhered to the overlying skin (not shown). Vhl 2B/2B teratomas (Figure 3b , left) were also grossly hemorrhagic compared with Vhl 2B/ þ (Figure 3b , right) teratomas. Histologically, Vhl À/À teratomas were characterized by hemangioma (*) formation (Figure 3e ), which was markedly enhanced in Vhl 2B/2B teratomas (Figure 3f ).
To determine whether Type 2B mutant pVhl preserves HIF regulation in vivo, teratomas were analysed for HIF-1a and HIF-2a protein expression by immunoblot, confirming low levels of both HIF factors (Supplementary Figure 2 ). To evaluate the effect on target gene expression, we performed qRT-PCR for the panel of HIF target genes described above in three independent sets of teratomas. In one representative set (Figure 3g ), the Vhl À/À teratoma displayed highly significant (Po0.001) overexpression of three of the four HIF targets relative to the J1 teratoma: Vegf (1.99-fold), EglN3 (3.15-fold) and Pfk1 (2.12-fold). In contrast to ES cells, the Vhl 2B/2B -derived teratoma exhibited significant overexpression of both EglN3 (1.46-fold, Po0.05) and Vegf (1.87-fold, Po0.001) but failed to overexpress the HIF-1a-specific target Pfk1. Glut1 expression was not elevated for either Vhl mutant in this differentiated system.
To explore the differences in vascular proclivities between Vhl À/À and Vhl 2B/2B teratomas, we performed a screen for candidate angiogenesis-related genes (Supplementary Table 1 and Figure 4 ). Four novel angiogenesis-related candidate genes, in addition to Vegfa, were uncovered in the candidate screen and validated by qRT-PCR with independent primers: VE-cadherin (Cdh5), the TgfbR endothelial coreceptor endoglin (Eng), Vegf receptor 2 (Kdr), and the Vegfr2 coreceptor neuropilin-1 (Nrp1). All four are considered direct HIF targets (Sanchez-Elsner et al., 2002; Elvert et al., 2003; Brusselmans et al., 2005; Le Bras et al., 2007) . Although both the Vhl À/À and Vhl 2B/2B teratomas significantly overexpressed Cdh5, Eng and Kdr relative to the J1 teratoma, the Vhl 2B/2B teratoma additionally significantly (Po0.001) overexpressed Nrp1 relative to both J1 and Vhl À/À (Figure 4) .
Homozygosity for Type 2B Vhl confers embryonic lethality
To examine 2B mutant pVhl function in murine development in vivo, we derived Vhl 2B/ þ knock-in mice from our targeted murine ES cells. Interheterozygous matings resulted in a 2:1 ratio of Vhl 2B/ þ to wildtype pups and a complete absence of Vhl 2B/2B pups (Table 1) . To pinpoint the window of Vhl 2B/2B intrauterine demise, we genotyped embryos resulting from timed matings at embryonic day (E) 9.5 and E10.5. Although Vhl 2B/2B embryos were present at near-expected levels at E9.5, only one Vhl 2B/2B embryo (3%) survived at E10.5. As reliance switches from yolk sac to placenta around E9.5 (Alvarez-Silva et al., 2003) , Vhl 2B/2B embryonic lethality observed at E9.5-E10.5 implicates placental failure.
Vhl À/À embryos display embryonic lethality at E9.5-E12.5 because of an embryonic origin defect in placental labyrinth vascularization. While the presumptive Vhl À/À labyrinth is normal in histological appearance at E9.5, Vhl À/À allantoic vessels fail to invade the chorionic plate, preventing the induction of chorionic plate trophoblast cell differentiation into syncitiotrophoblast cells and later manifesting as an absence of fetal blood spaces in the labyrinth at E10.5 (Gnarra et al., 1997) . To visualize whether the 2B mutant Vhl allele acts similarly to the null allele in the placenta, we compared wild-type (not shown), Vhl 2B/ þ and Vhl 2B/2B placentas by hematoxylin and eosin (H&E) for morphology and immunohistochemistry for pVhl and the HIF target Vegfa. By H&E, representative E9.5 Vhl 2B/ þ (Figure 5a ) and Vhl 2B/2B (Figure 5d ) placentas displayed comparable chorionic villous fold formation and maternal red blood cell content in the spongiotrophoblast layer, but allantoic vessels, demarcated by the presence of nucleated fetal red blood cells (*), invaded the chorionic villi to a lesser extent in the Vhl 2B/2B placenta. Despite the reduced Type 2B pVhl levels observed by immunoblot in Vhl 2B/2B ES cells, spongiotrophoblast and giant cell pVhl expression were comparable between representative Vhl 2B/2B (Figure 5e ) and Vhl 2B/ þ (Figure 5b ) placentas by immunohistochemistry. Finally, consistent with the findings in Vhl À/À placentas at E10.5 (Gnarra et al., 1997) , Vhl 2B/2B placenta (Figure 5f ) displayed absent or greatly reduced spongiotrophoblast and giant cell Vegf expression relative to Vhl 2B/ þ (Figure 5c ) by IHC. Although perhaps counter-intuitive in the context of Vhl mutation, decreased Vegf expression is a marker of placental failure rather than an indicator of HIF dysregulation in the murine placenta (Voss et al., 2000) .
As E9.5 embryos were the only Vhl 2B/2B animal tissues available for molecular study, we used these tissues to analyse the competence of Type 2B pVhl to regulate HIF target genes in vivo. Though Vhl 2B/2B embryos are grossly and histologically normal at E9.5, we hypothesized that they might still show subtle HIF target gene dysregulation. qRT-PCR on three Vhl 2B/2B E9.5 embryos showed significant (Po0.05) overexpression of the four HIF target genes studied relative to a Vhl 2B/ þ E9.5 embryo, paralleling the effect of Vhl mutation on HIF-regulated signaling observed in the differentiated teratoma model system (Figure 5g ): Vegf (average 1.54-fold), Glut1 (average 2.60-fold), EglN3 (average 3.53-fold) and Pfk1 (average 1.88-fold). In notable contrast to ES cells and teratomas and in keeping with the reported highly tissue-and context-specific transcriptional effects of HIF stabilization, homozygosity for the 2B Vhl allele produced sufficient HIF-1a dysregulation to permit the overexpression of the HIF-1a-specific target Pfk1 in the E9.5 embryo, with potential contribution by physiological embryonic hypoxia.
Heterozygous Type 2B Vhl mice develop renal cysts As Type 2B VHL disease predisposes to pheochromocytoma, hemangioblastoma and ccRCC in humans, Vhl 2B/ þ mice (n ¼ 105) were aged to 3, 6, 9, 12 and 18 months and observed for tumor susceptibility. Representative H&E images of Vhl 2B/ þ tissues at 12 months are presented in Figure 6a -c. Similar to earlier models, Vhl 2B/ þ mice displayed frequent enlarged vessels (angiectasis) in the kidney and adrenal gland (Figure 6b*; Gnarra et al., 1997; Haase et al., 2001; Ma et al., 2003) and renal cortical microcysts (3%, Figure 6a , Cy) (Haase et al., 2001) . Renal cortical cysts were not observed in wild-type littermates. In contrast to earlier studies, Vhl 2B/ þ liver histology was uniformly normal (Figure 6c ).
Transplacental mutagenesis promotes renal tumorigenesis in Type 2B Vhl mice
We hypothesized that accelerating somatic mutations through mutagenesis might reveal predisposition to cancer development in Vhl 2B/ þ mice. Transplacental Nethyl-N-nitrosourea (ENU) mutagenesis has been used successfully to augment renal cystogenesis in mouse models of tuberous sclerosis (Kobayashi et al., 1999) , another renal tumor predisposition syndrome, and therefore was an ideal method for accelerating progression in our model. Wild-type and Vhl 2B/ þ embryos from timed interheterozygous matings were treated with ENU at E14.5 and allowed to age to four (n ¼ 12) and 12 months (n ¼ 24) in a pilot study. At sacrifice, grossly abnormal organs and organs of interest were harvested. Renal lesions observed in mutagenized mice are summarized in Table 2 . At 4 months, both wild-type (2/4) and Vhl 2B/ þ (6/8) mutagenized mice displayed macroscopic subpleural lung nodules, indicating successful ENU mutagenesis (Miller, 2004) . Both wild-type and Vhl 2B/ þ mutagenized mice displayed simple and papillary cortical renal microcysts on H&E-stained sections, suggesting that ENU mutagenesis effectively promotes benign renal cyst formation in this C57BL/6 genetic background. Although all three papillary renal cysts observed in mutagenized wild-type mice displayed benign histology, the papillary cyst observed in a mutagenized Vhl 2B/ þ mouse displayed preneoplastic changes (not shown).
At 12 months, histological findings in wild-type mutagenized mice were limited to benign papillary cysts (Figure 6d ). However, Vhl 2B/ þ mutagenized mice (2/10) developed pathological findings typical of VHL disease. (e-f) Histological analysis of ENU-mutagenized Vhl 2B/ þ mice by H&E stain at Â 20 magnification. Although ENU mutagenesis promoted benign simple and papillary microcysts formation in both Vhl 2B/ þ (not shown) and wild-type littermates (d), borderline adenoma/adenocarcinoma (e) and adenocarcinoma (f) were selectively observed in mutagenized Vhl 2B/ þ mice at 12 months. Scale bars indicate 100 mm.
One Vhl 2B/ þ mouse developed a borderline clear-cell adenoma/adenocarcinoma (Figure 6e ) featuring a large nest of cells (alveolus) with clear-cell histology, vascular stroma and absent tubular architecture, as well as several clear-cell alveoli invading into the underlying renal cortex. A second affected Vhl 2B/ þ mouse developed adenocarcinoma (Figure 6f ) featuring nests of clear cells, central necrosis, absent tubular architecture, vascular stroma and a poorly defined border. Statistical analysis suggested that Vhl mutation correlated with or trended toward development of neoplasia at 12 months (Pearson's w 2 -test, P ¼ 0.037; Fisher's exact test, P ¼ 0.101).
Discussion
Germline Type 2B missense mutations in VHL predispose to ccRCC; central nervous sytem and retinal hemangioblastoma; and pheochromocytoma and paraganglioma. In our murine gene replacement system, which models one VHL type 2B disease mutation, R167Q pVhl generated a unique pattern of HIF-1a and HIF-2a dysregulations, differing from Vhl-null both in degree and ratio of HIF stabilization as well as in functional outcome in in vitro and in vivo studies. Our gene replacement system takes advantage of the euploid genetic background of murine ES cells and avoids the potential mouse-human interactions and over-and misexpression artifacts inherent to transgenic models. We observed reduced levels of 2B mutant pVhl protein in homozygous ES cells, supporting the hypothesis that ccRCC-predisposing VHL missense mutations produce less stable proteins, as posited on the basis of structure analysis Knauth et al., 2006) . In contrast to Vhl À/À ES cells, Vhl 2B/2B knock-in ES cells expressed low basal levels of HIF-1a and HIF-2a and induced both subunits physiologically in response to the hypoxia mimetic CoCl 2 . Consistent with this finding, Vhl 2B/2B ES cells displayed wild-type levels of four HIF target genes studied, suggesting that HIF-1a levels in Vhl 2B/2B cells failed to surpass a threshold required for transcriptional activation at target promoters in this cell type. The differentiated teratoma system allowed the observation of 2B mutant pVhl function in a setting permissive for both HIF-1a and HIF-2a transcriptional activity. An earlier work in Vhl À/À teratomas has shown that maximal activation of both HIF-1a and HIF-2a promotes angiogenesis but retards three-dimensional tumor growth (Mack et al., 2003) . Genetic knockout of HIF-1a (Carmeliet et al., 1998) or replacement of HIF-1a with HIF-2a (Covello et al., 2005) in teratomas enhances tumor growth and implicates HIF-1a as the growth-suppressive factor in this assay. In our studies, Vhl À/À teratomas likewise displayed a growth disadvantage relative to wild type and additionally featured the overexpression of the joint HIF targets Vegfa and EglN3 and the HIF-1a-specific target Pfk1, all indicating HIF-1a and HIF-2a stabilizations. Vhl 2B/2B teratomas, in contrast, displayed a marked growth advantage relative to wild-type and overexpression of Vegfa and EglN3, but not Pfk1, suggestive of subthreshold HIF-1a, but sufficient HIF-2a stabilization to promote transcriptional activity.
The placental failure and lethality observed in Vhl 2B/2B embryos at E9.5-E10.5 was consistent with severely hypomorphic mutant pVhl function in the embryonic allantoic endothelium. Reduced pVhl stability alone is unlikely to be the cause of Vhl 2B/2B embryonic lethality. First, 2B mutant pVhl levels in the E9.5 Vhl 2B/2B placenta were similar to pVhl levels observed in the E9.5 Vhl 2B/ þ placenta by IHC. Second, Vhl CP/CP mice are viable despite the measurable instability of R200W (CP) pVhl both in vitro and in murine tissues (Hickey et al., 2007) . Finally, there is evidence of more severe HIF dysregulation in this in vivo system, with induction of the HIF-1aspecific target Pfk1 indicating both HIF-1a and HIF-2a stabilization. Thus, although it remains possible that the degree of pVhl reduction has a threshold effect on early developmental events, the reduced levels in these models serves to unmask added levels of regulation of the HIF transcriptional network.
Vhl 2B/ þ mice developed renal cysts with frequency similar to that observed in Vhl þ /À mice (B3%) and likewise failed to develop dysplasia or renal adenocarcinoma, indicating that Vhl mutation alone is insufficient for invasive renal tumor formation in the murine kidney. To accelerate the accumulation of somatic mutations in this mouse model and reveal tumor predisposition, we mutagenized Vhl-initiated and wild-type littermate mice with transplacental ENU. At 12 months post-ENU, renal adenocarcinoma was observed in mutagenized Vhl 2B/ þ mice, representing the first demonstration of this tumor in a genetically predisposed mouse model and validating Vhl mutation as a tumor-initiating event in the development of RCC.
Our gene replacement model of the representative Type 2B R167Q Vhl mutation bolsters emerging 
Materials and methods
Generation of Vhl Type 2B ES cell lines and heterozygous mice Vhl exons 2 and 3 (E2 and E3) were cloned into targeting and mutagenesis vectors, respectively, from a BAC clone as described previously (Covello et al., 2005; Hickey et al., 2007) . PCR-based site-directed mutagenesis of G-A at position 518 was performed using forward primer 5 0 -AGAGCCTGGT CAAGCCTGAGAACTA-3 0 and reverse primer 5 0 -GCAC AACCTGAAGGCACCGCTCTTT-3 0 . The G518A mutant E3 fragment was then cloned into pLNT-E2 adjacent to the neo R cassette (pLNT-E2-E3), and reconfirmed with bidirectional sequencing.
The pLNT-E2-E3 targeting construct ( Figure 1b ) was electroporated into Vhl wild-type J1 strain Sv/129 ES cells for gene replacement at the endogenous murine Vhl locus. Homologous recombinants heterozygous for the Vhl 2B neoÀin allele were selected by gancyclovir and neomycin resistance, and positive clones confirmed by southern blot analysis. Conversion of the second Vhl allele was achieved by selection with increasing amounts of neomycin to yield ES cells homozygous for the Vhl 2B neoÀin allele. Vhl 2B neoÀin/ þ and Vhl 2B neoÀin/2B neoÀin ES cells were transiently transfected with a cre-expressing vector to remove the floxed neo R cassette. The ES cells were screened at each stage by southern blot for in vitro and in vivo studies of Type 2B mutant pVhl function.
Animal Models Core (University of Pennsylvania) staff injected karyotyped Vhl 2B neoÀin/ þ ES cells into C57BL/6 blastocysts. The chimeric blastocysts were then implanted in pseudopregnant C57BL/6 females. Highly chimeric mice (F0) were selected by Agouti coat color for crossing to C57BL/6 females. Germline transmission of the targeted allele to Agouti offspring (F1) was confirmed by Southern blot. A Vhl 2B neoÀin/ þ line was crossed to a cre deleter mouse strain (EIIa-cre) (Williams-Simons and Westphal, 1999) for multiple generations, with excision of the floxed neo R cassette verified by southern blot, and then backcrossed to C57BL/6 to make a Vhl 2B/ þ founder line. All subsequent generations were genotyped by restriction PCR using PCR primers flanking a novel HpyIV restriction site introduced by the G518A Vhl mutation (Figure 1d ).
All mouse procedures were approved by the Institutional Animal Care and Use Committees of the University of Pennsylvania and University of North Carolina.
Cell culture studies
Cell culture studies were performed at 37 1C, 5% CO 2 . ES cell lines were maintained in ES media consisting of high glucose Dulbecco's modified eagle medium (Gibco, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum, L-glutamine, b-mercaptoethanol, nonessential amino acids, and leukemia inhibitory factor, and grown on gelatin-coated tissue culturegrade plates (Corning, Corning, NY, USA). For chemical hypoxia mimetic experiments, cells were grown in the presence or absence of CoCl 2 (100 mM) for 4 h. For proteasome inhibition experiments, cells were treated with vehicle (DMSO) or MG-132 (5 mM, Calbiochem, San Diego, CA, USA) for 4 h.
For in vivo teratoma studies, undifferentiated ES cells of each genotype (5 Â 10 6 ) were injected subcutaneously into the flanks of nu/nu mice (Taconic Labs, Hudson, NY, USA) and allowed to grow for six weeks with weekly caliper measurements of tumor size. Harvested tumors were bisected and either flashfrozen in liquid nitrogen for molecular analysis or formalin-fixed and paraffin-embedded for histological analysis.
Molecular analysis of Vhl, HIF and HIF targets
Whole-cell protein extracts for immunoblot were prepared in NET lysis buffer (20 mM Tris, 100 mM NaCl, 1 mM EDTA, 1% NP-40) and quantitated by Bradford assay. Immunoblot primary antibodies used were pVhl (M20 and FL181, Santa Cruz Biotechnology, Santa Cruz, CA, USA), HIF-1a (10006421, Cayman Chemical, Ann Arbor, MI, USA), HIF-2a (NB100-122, Novus Biologicals, Littleton, CO, USA) and eEF2 (Cell Signaling Technology, Danvers, MA, USA). Murine Vegf Enzyme-Linked ImmunoSorbent assay was performed on conditioned medium from cultured ES cells (R and D Systems, Minneapolis, MN, USA).
RNA isolation from ES cells, teratomas and E9.5 embryos was performed using the RNeasy Mini system according to the manufacturer's instructions (Qiagen, Germantown, MD, USA) and quantified by the ultraviolet spectroscopy. cDNA was prepared from 0.5 mg of RNA using Superscript reverse transcription reagents (Stratagene, Cedar Creek, TX, USA). qRT-PCR was performed in triplicate using stock commercial primer-probe sets for Vhl, Vegfa, Glut1, EglN3, Pfk1 and 18S ribosomal subunit according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). A candidate screen for teratoma hemangioma-associated genes was performed in triplicate on the RT 2 Profiler Mouse Angiogenesis Array using cycle parameters according to manufacturer's instructions (SABiosciences, Frederick, MD, USA). Genes identified for further validation were analysed by qRT-PCR in triplicate using stock commercial primer-probe sets for Cdh5, Eng, Kdr, Nrp1, Vegfc and 18S ribosomal subunit and cycle parameters according to the manufacturer's instructions (Applied Biosystems). All qRT-PCR output raw cycle thresholds were normalized to the internal 18S ribosomal RNA standard.
Embryonic lethality and transplacental ENU mutagenesis studies
Vhl 2B/ þ mice were set up for timed interheterozygous mating. Embyronic day (E) 0.5 was defined as noon on the day the vaginal plug was observed, and embryos and placentas were harvested at E9.5 and E10.5. For placental studies, embryos were examined for gross defects and genotyped by restriction PCR, and placentas were processed for histological examination. For embryonic studies, E9.5 embryos were used for both RNA extraction and genotyping by restriction PCR.
For transplacental mutagenesis studies, intraperitoneal (i.p.) injection of 50 mg/kg ENU (Sigma, St Louis, MO, USA) dissolved in ethanol was administered to the pregnant dam at E14.5 (Kobayashi et al., 1999) . Mutagenized Vhl 2B/ þ and wildtype littermates were aged in 4-and 12-month cohorts and sacrificed for gross and histological examination.
Histological analysis of murine tissues
Harvested tissues were fixed in 10% buffered formalin. Paraffin-embedded tissues were sectioned and stained with H&E or for pVhl (FL181) or Vegfa (VG-1, Santa Cruz).
Statistical analysis
A two-tailed Student's t-test was used to make paired comparisons for qRT-PCR and Vegf enzyme-linked immunoSorbent assay data. A value of Pp0.05 was used as the threshold for statistical significance. Pearson's w 2and Fisher's exact tests were used to compare the development of neoplasia in wild-type versus Vhl-mutant mutagenized mice.
